Indivior Pharmaceuticals, Inc. (INDV) · Sep 15, 2026 · Agreement terminated

Indivior accelerates Reckitt tablet supply exit, but replacement awaits validation

Supply agreement ends Jan. 15, 2027 — Termination accelerated to January 15, 2027; replacement supplier validation pending

Indivior will end Reckitt’s SUBOXONE and SUBUTEX tablet supply four months early. The transition is funded, but replacement manufacturing is not yet validated.

Indivior is in an execution phase centered on expanding SUBLOCADE while still relying heavily on buprenorphine-based sublingual products, including SUBOXONE Tablet and SUBUTEX Tablet; it also remains dependent on third-party contract manufacturers.

The filing accelerates the exit from Reckitt’s tablet manufacturing, but does not yet complete the replacement. Indivior and Reckitt agreed to move the Copacker Supply Agreement’s termination date to January 15, 2027, with Reckitt producing additional units before then. 〔0〕 This removes a legacy supply relationship sooner than previously scheduled, but the new supplier’s obligations become enforceable only after its manufacturing process is validated. 〔1〕

The financial burden is contained; the operational risk is the unresolved piece. Indivior will cover volume shortfall, asset disposal, depreciation recovery, redundancy, incentive, and potential third-party costs, but the filing says those costs are fixed or capped and immaterial. 〔2〕 That makes this less a near-term earnings event than a supply-continuity transition: the company has identified a replacement, but has not yet demonstrated that the replacement is fully validated and ready.

Bottom line: This is a strategically sensible cleanup of a legacy manufacturing arrangement, but it adds a short-term execution checkpoint around validation. It changes the supply-chain setup more than the financial outlook today.

What to watch next

Validation of the new supplier’s manufacturing process

Original filing on SEC EDGAR

More Indivior Pharmaceuticals, Inc. news

Indivior accelerates Reckitt tablet supply exit, but replacement awaits validation | INDV Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.